What You Should Know:
- Motif Neurotech, a pioneer in minimally-invasive bioelectronics for mental health, announced today an impressive $18.75 million Series A funding round. Led by Arboretum Ventures, the investment saw participation from prominent players like KdT Ventures, Satori Neuro, and Dolby Family Ventures, alongside existing supporters Divergent Capital and PsyMed Ventures.
- Motif Neurotech's innovative approach represents a potential paradigm shift in mental health treatment.
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Precision Psychiatry: Circular Genomics Secures $8.3M to Tackle Depression with CircRNA Test
What You Should Know:
- Circular Genomics, a pioneer in unlocking the secrets of circular RNA (circRNA) for precision psychiatry and neurology, has secured $8.3 million in a Series A funding round. Led by Mountain Group Partners, this vital investment brings on board new partner UNM Rainforest Innovations and bolsters support from existing investors like Cottonwood Technology Fund and Tramway Venture Partners.
- The new funding will empower Circular Genomics to build and scale commercial
Read More
Invitae Sells Reproductive Health Assets to Natera for Up to $52.5M
What You Should Know:
- Invitae (NYSE: NVTA), a medical genetics company, announced the completion of its sale of certain reproductive health assets, including carrier screening and non-invasive prenatal screening (NIPS), to Natera (NASDAQ: NTRA).
- The transaction is valued at up to $52.5M, comprised of cash, milestone payments, and litigation credits.
Streamlining Focus on Oncology and Rare Disease
This strategic move streamlines Invitae's operations and allows them to focus their
Read More
Leveraging RWD & Tech: Diversifying Clinical Research for Real-World Impact
In today's complex healthcare landscape, real-world data (RWD) is increasingly valued for its information regarding diverse patient populations. Clinical research sites are an essential part of the RWD collection process, which increasingly leverages advanced technologies that enhance data collection, analysis and informed decision-making.
RWD can accelerate development timelines and augment clinical trial insights with key observational results from a wider and more diverse range of
Read More
The New Era of Clinical Trials: Adopting Electronic Informed Consent
The clinical trials landscape continues to evolve and with it, an exponential growth in the adoption of electronic informed consent (eConsent) solutions. These solutions deliver a myriad of benefits for trial sponsors, sites and patients. However, there is still some reluctance to adopt these solutions due to perceived costs associated with implementation and training.
The Importance of eConsent
Clinical trials are evolving with novel designs, hybrid and decentralized
Read More
13 Potential Blockbuster Drugs and Gamechangers to Watch in 2024
What You Should Know:
- Clarivate Plc, a provider of trusted information and insights, today unveiled its highly anticipated 2024 Drugs to Watch report, shining a spotlight on 13 cutting-edge therapeutics poised to revolutionize healthcare in the coming year.
- These promising drugs span a diverse range of conditions, from debilitating diseases like sickle cell anemia and multiple myeloma to common ailments like chronic obstructive pulmonary disease (COPD) and age-related macular
Read More
Labcorp & Hawthorne Effect Partner to Supercharge Decentralized Clinical Trials
What You Should Know:
- Labcorp, a global leader in innovative laboratory services, and Hawthorne Effect, Inc., a pioneer in technology-driven clinical trial solutions, have announced a groundbreaking partnership to revolutionize clinical trials with a focus on decentralization.
- This collaboration aims to unlock unprecedented levels of patient diversity, reduce site burden, and accelerate study timelines for pharmaceutical, biotech, and medical device sponsors.
Decentralization: The
Read More
Debiopharm and ThinkingNodeLife.ai Partner on AI-Driven Cancer Drug Development
What You Should Know:
- Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug.
- This strategic partnership combines Debiopharm's deep pharmaceutical expertise with TNL's revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation.
Unlocking the Hidden Potential of a
Read More
Deepcell & NVIDIA Partner to Develop Generative AI Models for Single Cell Morphology
What You Should Know:
Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.Deepcell will incorporate NVIDIA AI into its single cell analysis technology, working collaboratively with NVIDIA to codevelop new uses for generative AI and multimodal applications in cell biology. The
Read More
Clinical Trial Payments: Optimizing the Path Forward for Site Payments
Escalating competition for clinical trial sites, in tandem with other industry-wide challenges such as changing regulations; a lack of bandwidth and resources; identifying ideal sites and recruiting and retaining patients, are posing significant obstacles for sponsors and site teams within a global study portfolio, particularly in relation to clinical trial payments. Factors such as decentralized clinical trials, inflation and site attrition contribute to inconsistencies and financial confusion,
Read More
